A longitudinal, relationship-based case management approach significantly reduced health care costs and improved quality of life for Medicaid enrollees with complex needs over 1 year. Objectives: This ...

BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma Early-phase clinical trials (EPCTs) have been ...

Objective The aims of this study, which uses a trial within a cohort design, were to determine the efficacy of a web-based intervention to increase moderate-to-vigorous intensity physical activity ...

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded ...

MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced detailed efficacy ...

Final patient in first cohort dosed with RC220 in cardioprotection and anticancer synergy Phase I trial in advanced solid ...

The company anticipates completing the expansion cohort for preeclampsia in the first half of 2026 and expects the interim analysis of the ReMEDy2 stroke trial based on the first 200 patients in the ...

Tenaya Therapeutics updates on TN-201 and TN-401 gene therapies' clinical trials for cardiomyopathies, with data anticipated in 2025. Tenaya Therapeutics, a clinical-stage biotechnology company ...

- Proof-of-activity now established for PBGENE-HBV, the first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated DNA, with the goal of ...

Anixa Biosciences (ANIX) announced it has completed dosing of the fourth cohort in its ongoing Phase 1 clinical trial evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian ...